Johnson & Johnson has reached a deal to buy all the outstanding equity of Dutch vaccines maker Crucell that it doesn't already own for about $2.43 billion -- just as some major Crucell shareholders say the bid's too low, according to FiercePharma.
Johnson & Johnson became the latest large healthcare group to expand into vaccines with the launch of a $2.3 billion takeover offer for the Dutch company Crucell, according to the Financial Times (registration required).
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Pfizer-Wyeth fallout: At a time when many small biotech companies are desperate for cash, neither Pfizer nor Wyeth will be able to enter into new deals anytime soon.